AUG 11, 2020 1:29 PM PDT

FDA Approves New Opioid for Short-Term Use

WRITTEN BY: Annie Lennon

The US Food and Drug Administration has announced the approval of Olinvyk (oliceridine), a new opioid that can help manage moderate to severe acute pain in adults. 

To test the drug, researchers enrolled 1,535 patients with moderate to severe acute pain in randomized, placebo-controlled, open-label trials. Administered to patients having undergone bunion or abdominal surgery, patients on the drug reported decreased pain when compared to those taking the placebo. 

Approved for both inpatient and outpatient procedures, the drug is only available for short-term usage. Meanwhile, its maximum approved dose is 27mg, and its target market is high-risk patients, such as the elderly, those who are obese, or have renal problems. 

Overall, the new drug has a similar safety profile to other opioids, and the FDA warns potential users and medical practitioners alike of its potential for abuse. Nevertheless, like other opioids, its most common side effects include nausea, vomiting, dizziness, headaches, and constipation. The FDA also notes that the drug should not be given to patients with significant respiratory depression and acute or severe bronchial asthma in an unmonitored setting without equipment for emergency resuscitation. 

“Addressing the opioid crisis remains a top priority for the FDA. We will continue to do everything we can to reduce the number of Americans who are addicted to opioids and cut the rate of new addiction through a number of cross-agency initiatives,” says Douglas Throckmorton M.D., deputy director for regulatory programs in the FDA’s Center for Drug Evaluation and Research. 

“Importantly, the FDA will only approve new drug applications, including those for opioid medications, following a rigorous review to evaluate the risks and benefits and ultimate determination that the data support safety and effectiveness. Of note, this particular medication is only indicated for use in a controlled clinical setting, meaning under medical supervision and not for use in a take-home prescription.”

 

Sources: BioworldFDA

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JAN 13, 2021
Immunology
Antibodies Gain the Upper Hand Against Sly Tumors
JAN 13, 2021
Antibodies Gain the Upper Hand Against Sly Tumors
Tumors use ingenious approaches to stay just out of reach of immune cells on patrol and avoid detection. Indeed, cancer ...
MAR 09, 2021
Drug Discovery & Development
Personalized Psychedelic Assisted-Therapy
MAR 09, 2021
Personalized Psychedelic Assisted-Therapy
Psychedelics have long been known for their therapeutic in treating mental health disorders. However, there remains a co ...
APR 14, 2021
Cancer
Cell Viability- Where to Begin?
APR 14, 2021
Cell Viability- Where to Begin?
Written By: Author As I pondered the title of this article, my thoughts immediately went back to a request by my Ph.D. a ...
APR 22, 2021
Drug Discovery & Development
New Method To Fast Track Drug Development
APR 22, 2021
New Method To Fast Track Drug Development
The time it takes to respond to disease outbreaks is critical. But designing drugs to combat these disease outbreaks is ...
APR 27, 2021
Cannabis Sciences
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
APR 27, 2021
CBD Doesn't Reduce Pain, but Makes it Less Unpleasant
While anecdotal reports tout cannabidiol’s (CBD) utility for pain relief, up until now, there’s been limited ...
MAY 04, 2021
Health & Medicine
Micro-dosing Inhaler Breakthrough for Medical Cannabis
MAY 04, 2021
Micro-dosing Inhaler Breakthrough for Medical Cannabis
In a leap that will eliminate the risks of vaping or smoking, Canada has just approved an Israeli-made inhaler that is a ...
Loading Comments...